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The cellular response to p53 activation varies greatly in a
stimulus- and cell type-speciﬁc manner. Dissecting the
molecular mechanisms deﬁning these cell fate choices will
assist the development of effective p53-based cancer thera-
pies and also illuminate fundamental processes by which
gene networks control cellular behaviour. Using an experi-
mental system wherein stimulus-speciﬁc p53 responses are
elicited by non-genotoxic versus genotoxic agents, we dis-
covered a novel mechanism that determines whether cells
undergo proliferation arrest or cell death. Strikingly, we
observe that key mediators of cell-cycle arrest (p21, 14-3-
3r) and apoptosis (PUMA, BAX) are equally activated regard-
less of outcome. In fact, arresting cells display strong trans-
location of PUMA and BAX to the mitochondria, yet fail to
release cytochrome C or activate caspases. Surprisingly, the
key differential events in apoptotic cells are p53-dependent
activation of the DR4 death receptor pathway, caspase 8-
mediated cleavage of BID, and BID-dependent activation of
poised BAX at the mitochondria. These results reveal a
previously unappreciated role for DR4 and the extrinsic
apoptotic pathway in cell fate choice following p53 activation.
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Introduction
The p53 network is the most commonly deregulated gene
circuitry in human cancer. More than half of tumours carry
mutations in the TP53 gene while in the remaining fraction
p53 is likely attenuated by hyperactivation of repressors such
as MDM2 and MDM4 (Brown et al, 2009). The p53 protein
acts mostly as a transcription factor, but cytoplasmic func-
tions of p53 have also been documented (Laptenko and
Prives, 2006; Green and Kroemer, 2009). p53 behaves as a
signalling node that is activated by a plethora of stress signals
and it in turn participates in the orchestration of various
cellular responses including, but not restricted to, cell-cycle
arrest, senescence, apoptosis, and autophagy (Vousden and
Prives, 2009). As observed for other master transcriptional
regulators of cell behaviour, the cellular response to p53
activation varies greatly with the context. Stimulus- and cell
type-speciﬁc p53 responses have been extensively documen-
ted (Vousden and Lu, 2002). The same cell type may undergo
strikingly different p53-dependent responses upon exposure
to distinct stress signals, whereas the same p53-activating
agent can trigger dissimilar responses across various cell
types. Despite many research efforts in this arena, we still
lack a thorough understanding of how alternative p53 re-
sponses are deﬁned. The biomedical importance of this
problem cannot be overstated. Elegant studies in animal
models have clearly established that reactivation of p53 in
tumours is a valid therapeutic strategy, as increased p53
activity leads to tumour clearance via senescence or cell
death (Ventura et al, 2007; Xue et al, 2007). However, any
efforts to pharmacologically reactivate mutant p53 or block the
repressive effects of MDM2/MDM4 on wild-type p53 will be
hampered by the fact that p53 is highly pleiotropic. This
pleiotropy has become evident with the advent of inhibitors
of the p53–MDM2 interaction such as Nutlin-3 (Nut3), a non-
genotoxic small molecule that binds to MDM2 and prevents its
association with p53 (Vassilev et al,2 0 0 4 ) .R e m a r k a b l y ,m o s t
cancer cell types fail to undergo p53-dependent apoptosis
following Nut3 treatment, instead adopting a reversible cell-
cycle arrest phenotype (Tovar et al, 2006; Paris et al, 2008).
However, as shown in this report, these ‘Nutlin-resistant’ cell
types effectively undergo p53-dependent apoptosis in response
to a genotoxic stimulus. Thus, understanding the molecular
mechanisms driving stimulus-speciﬁc p53 responses is a
prerequisite for the successful design of p53-based therapies.
Pleiotropy and context dependence are the hallmarks of
biological systems. The overall impact of a given gene
product on the function of a cell, tissue or organism is
ultimately deﬁned by myriad interactions with other gene
products. Context-dependent variations in this web of inter-
actions deﬁne the biological function of a gene in different
scenarios. The p53 network provides an excellent paradigm
to investigate how gene networks orchestrate alternative cell
fates. Several models have been proposed to explain how
different p53-dependent responses are established (Vousden
and Lu, 2002; Espinosa, 2008). p53-centric models ascribe the
cell fate choice to molecular events affecting the p53 mole-
cule itself. For example, p53 post-translational modiﬁcations
and p53-binding proteins have been shown to modulate its
transcriptional competence in a gene-speciﬁc manner
(Samuels-Lev et al, 2001; Sykes et al, 2006; Tang et al,
2006; Das et al, 2007). Alternative models focus instead on
the fact that p53 target genes themselves are subject to
multiple regulatory inﬂuences acting at both the transcrip-
tional and post-transcriptional levels (Espinosa et al, 2003;
Gomes et al, 2006; Donner et al, 2007b; Tanaka et al,2 0 0 7 ;
Paris et al, 2008; Beckerman et al, 2009; Morachis et al, 2010).
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1266According to the latter view, the transcriptional competence of
p53 is largely invariant in different contexts, and the cell fate
choice is instead deﬁned by variations in p53-autonomous
mechanisms affecting its target genes. Despite their differences,
both models converge on the assumption that cell fate choice
results from an imbalance in the activity of p53 target genes
acting in different pathways. For example, it is well established
that p53-dependent cell-cycle arrest is mostly mediated by cell-
cycle regulators such as CDKN1A (p21) and SFN (14-3-3s)
(el-Deiry et al, 1993; Hermeking et al, 1997), while p53-
dependent apoptosis is mediated by pro-apoptotic factors
such as the mitochondrial pore protein BAX and the BH3-
only protein BBC3 (PUMA) (Miyashita and Reed, 1995; Nakano
and Vousden, 2001; Yu et al, 2003). Thus, the prevailing views
support the idea that differential transcriptional output between
the p21 and 14-3-3s loci versus the BAX and PUMA loci is a key
determinant of cell fate choice (Sykes et al,2 0 0 6 ;T a n get al,
2006; Das et al, 2007). However, a formal demonstration of this
model is lacking. In fact, we show here that stimulus-speciﬁc
responses to p53 activation can be delivered without any
difference in the transcriptional output of these key genes.
Using a model system where the two major p53 responses,
cell-cycle arrest and apoptosis, are triggered alternatively by
simply using different p53-activating agents, we investigated
the contribution of B20 components of the p53 network to
cell fate choice. In our system, cancer cells are driven into
p53-dependent cell-cycle arrest with Nut3 versus p53-depen-
dent apoptosis with the anti-metabolite 5-ﬂuorouracil (5FU).
Strikingly, gene expression analysis at the RNA and protein
levels reveals that cells undergoing p53-dependent cell-cycle
arrest nevertheless display effective transactivation of PUMA
and several other pro-apoptotic target genes, concurrent with
translocation of BAX to the mitochondria. However, these
cells fail to release cytochrome C into the cytosol, activate
caspases or trigger apoptosis. Conversely, cells undergoing
p53-dependent apoptosis show strong transactivation of p21,
14-3-3s and other genes involved in cell-cycle arrest.
However, these cells fail to arrest and show instead p53-
dependent activation of caspases. Careful genetic dissection
of different components of the apoptotic apparatus led to the
unexpected observation that the key stimulus-speciﬁc mole-
cular events deﬁning cell fate choice are (1) p53-dependent
activation of caspase 8, (2) caspase 8-dependent activation of
the BH3-only protein BID, and (3) BID-dependent activation
of BAX. Interestingly, the p53 target gene DR4 is required for
all of these events to occur. DR4 expression is strongly
induced only in 5FU-treated cells via a combination of p53-
dependent transactivation and p53-independent mRNA sta-
bilization. Thus, p53 action is complemented by other stress-
induced events to tip the balance towards the apoptotic
response. These results demonstrate a critical role of the
extrinsic apoptotic pathway in cell fate choice and also
illuminate key molecular events deﬁning the shortcomings
of novel p53-based therapies.
Results
Cell fate choice to p53 activation is deﬁned by the
stimulus-speciﬁc activation of poised BAX at the
mitochondria
In order to uncover novel mechanisms contributing to
p53-dependent cell fate choices, we established a tissue
culture system in which p53 activation results in different
cellular fates depending on the p53-activating agent utilized.
Our group and others have previously demonstrated that
HCT116 cells undergo reversible p53-dependent cell-cycle
arrest upon treatment with Nut3 (Tovar et al, 2006; Paris
et al, 2008). In contrast, these same cells undergo robust p53-
dependent apoptosis upon treatment with 5FU (Figure 1A)
(Bunz et al, 1999). Interestingly, while both Nut3 and 5FU
induce equivalent p53 protein accumulation, only 5FU causes
release of cytochrome C into the cytosol, caspase 3 activation
and PARP cleavage, demonstrating that differences in p53
protein levels do not account for the stimulus-speciﬁc
responses seen in our paradigm (Figure 1B).
Work from several laboratories has put forth a model
wherein differential transcriptional activation of key p53
target genes mediating cell-cycle arrest, such as p21 and
14-3-3s, versus genes mediating apoptosis, such as PUMA
and BAX, can determine the cellular outcome to p53 activa-
tion (Samuels-Lev et al, 2001; Sykes et al, 2006; Tang et al,
2006; Das et al, 2007). Accordingly, we hypothesized that
stimulus-speciﬁc regulation of one or more of these genes
could steer the p53 response towards a speciﬁc outcome in
our system. Interestingly, both Nut3 and 5FU treatment lead
to identical accumulation of p21 and 14-3-3s protein
(Figure 1B). Thus, although it is well established that these
two cell-cycle regulators are required for p53-dependent cell-
cycle arrest (el-Deiry et al, 1993; Hermeking et al, 1997) and
that they cooperate to exert protective effects against 5FU-
induced apoptosis (Chan et al, 2000), they are clearly not the
determinants of cell fate choice in our system. PUMA and
BAX are direct transcriptional targets of p53 required for 5FU-
induced apoptosis (Miyashita and Reed, 1995; Nakano and
Vousden, 2001; Yu et al, 2001). Remarkably, Nut3 treatment
induces the accumulation of PUMA and BAX protein to levels
equal to or higher than those observed upon 5FU treatment
(Figure 1B). Furthermore, mitochondrial fractionation experi-
ments demonstrate that Nut3 treatment leads to effective
translocation of PUMA and BAX to the mitochondria
(Figure 1C, fractionation controls are shown in Supple-
mentary Figure S1). These observations suggest that physio-
logical induction and mitochondrial accumulation of these
key apoptotic factors is not sufﬁcient to trigger p53-depen-
dent cell death.
The lack of cytochrome C release into the cytosol of Nut3-
treated cells suggests that mitochondrial outer membrane
permeabilization (MOMP) is impaired under these condi-
tions. One explanation for this could be the failure of BAX to
oligomerize and form pores in the mitochondrial outer
membrane. To test this, we evaluated BAX oligomerization
using chemical crosslinking of mitochondrial fractions,
which revealed the existence of BAX oligomers in 5FU-
treated cells but not in cells treated with Nut3 (Figure 1D).
This suggests that in Nut3-treated cells, BAX fails to undergo
the requisite conformational change prior to oligomeriza-
tion (Kim et al, 2009). We investigated this possibility by
immunoprecipitating BAX with the conformation-speciﬁc
antibody 6A7, which speciﬁcally detects the activated con-
former of BAX (Hsu and Youle, 1997). Conﬁrming our
hypothesis, BAX activation is detectable in 5FU-treated
cells, but not in cells treated with Nut3 (Figure 1E). Taken
together, these data demonstrate that although Nut3 treat-
ment leads to effective accumulation of PUMA and BAX at
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MOMP and apoptosis.
BID is required for stimulus-speciﬁc BAX activation and
apoptosis
It is well established that MOMP is regulated by the balance
between pro- and anti-apoptotic members of the BCL2 protein
family, many of which are transcriptionally regulated by p53
in some cell types, such as BAX, PUMA, NOXA, BID and
BCL2 (Miyashita et al, 1994; Miyashita and Reed, 1995;
Nakano and Vousden, 2001; Wu et al,2 0 0 1 ;Y uet al, 2001;
Sax et al, 2002; Schuler et al, 2003). Having ruled out
differential expression of PUMA and BAX as responsible for
stimulus-speciﬁc MOMP in our system, we next examined the
expression of the pro-apoptotic BH3-only proteins NOXA,
BID, the truncated active form of BID (tBID), as well as the
anti-apoptotic proteins BCL2 and BCL-XL. Interestingly, we
observed both stimulus-speciﬁc induction of NOXA protein
and proteolytic activation of BID upon 5FU treatment
(Figure 2A). Stimulus-speciﬁc activation of NOXA and tBID
is also reﬂected in their mitochondrial levels (Figure 2B).
In contrast, the total and mitochondrial levels of BCL2 and
BCL-XL remain unchanged by either treatment (Figure 2A
and B). Differential induction of NOXA is also observed at
the mRNA level, and in agreement with a previous report
(Yu et al, 2001), we found that NOXA upregulation upon 5FU
treatment is p53-independent (Supplementary Figure S2).
Although BID has been described as a direct transcriptional
target of p53 in other settings (Sax et al, 2002), BID mRNA
expression is not induced by Nut3 or 5FU in our system
(Supplementary Figure S3). To test if differential activation
of NOXA and tBID contributes to cell fate choice in our
paradigm, we established stable knockdown cell lines for
each factor and measured the apoptotic response following
5FU treatment. Interestingly, reducing NOXA expression
well below basal levels has no signiﬁcant effect on 5FU-
induced apoptosis (Figure 2C and D). In contrast, BID
depletion signiﬁcantly reduces 5FU-induced apoptosis,
blocking cell death as effectively as a BAX knockout
(Figure 2E). Importantly, BID knockdown severely impairs
Figure 1 Stimulus-speciﬁc responses to p53 activation are deﬁned by differential BAX oligomerization. (A) HCT116 cells undergo p53-
dependent apoptosis in response to 5FU, but not Nut3. Cells were treated with Nut3 or 5FU for the indicated times, stained with Annexin-V-
FITC and analysed by ﬂow cytometry. Isogenic p53-null HCT116 cells are denoted as p53
 / . Data shown are the mean±s.d. of at least three
independent experiments. (B) Immunoblot analysis reveals that several genes mediating cell-cycle arrest and apoptosis are expressed equally
in response to Nut3 or 5FU treatment. Casp3* denotes the p19/17 doublet indicative of caspase 3 activation. (C) Nut3-treated cells accumulate
as much mitochondrial PUMA and BAX as do 5FU-treated cells. COX4 is a mitochondrial protein serving as a loading control. HCT116 cells
were treated as in (B) before preparation of mitochondrial fractions (see Supplementary Figure S1 for fractionation controls). (D)B A X
oligomerization is observed only in 5FU-treated cells. Filled circles on the right represent the predicted migration of BAX mono-, di-, tri-, and
tetramers. (E) Stimulus-speciﬁc activation of the BAX protein was detected by immunoprecipitation with the conformer-speciﬁc 6A7 antibody
followed by western blot. Figure source data can be found in Supplementary data.
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together, these data demonstrate that BID is an important
factor mediating apoptosis in response to 5FU, and suggests
that the failure of Nut3-activated p53 to induce BID cleavage
determines cell fate choice in our experimental model.
Stimulus-speciﬁc activation of caspase 8 is required for
BID cleavage and BAX activation
Caspase 8 is a major initiator caspase in the death receptor-
dependent (extrinsic) apoptotic pathway and a known med-
iator of BID cleavage in response to genotoxic stress (Li et al,
1998). Interestingly, we found that only 5FU treatment leads
to caspase 8 activation (Figure 3A) and that this event
requires p53 (Figure 3B). Furthermore, caspase 8 knockdown
strongly inhibits activation of executioner caspase 3, and
cleavage of the caspase 3 substrate, PARP (Figure 3C). In
fact, caspase 8-deﬁcient cells are signiﬁcantly impaired in
their ability to undergo apoptosis following 5FU treatment
(Figure 3D). Next, we asked whether caspase 8 is required for
BID cleavage in our system and found that indeed, proteolytic
processing of BID is greatly reduced in 5FU-treated cells
lacking caspase 8 (Figure 3E). Expectedly, BID cleavage
upon 5FU treatment also requires p53 (Figure 3B).
Importantly, BAX activation is signiﬁcantly blocked in cells
depleted of caspase 8 or BID as seen by immunoprecipitation
with 6A7 antibody (Figure 3F). Stimulus-speciﬁc activation of
caspase 8 was also observed in RKO colorectal cancer cells,
which also undergo cell-cycle arrest upon Nut3 treatment
Figure 2 BID cleavage is stimulus-speciﬁc and required for BAX oligomerization and apoptosis. (A) NOXA and tBID proteins accumulate in
5FU-treated, but not in Nut3-treated cells, whereas BCL2 and BCL-XL levels are similar between treatments. (B) Levels of mitochondria-
localized NOXA and tBID increase following 5FU, but not Nut3, whereas the levels of BCL2 and BCL-XL remain similar between treatments. The
COX4 panel is the same as in Figure 1C. (C) Immunoblot assessment of NOXA knockdown. (D) Apoptotic index assays show no signiﬁcant
effect of NOXA knockdown on 5FU-induced apoptosis. Data shown are the mean±s.d. (E) Apoptotic index assays indicate that BID knockdown
abrogates 5FU-induced apoptosis as effectively as BAX knockout. Data shown are the mean±s.d. (F) Western blot analysis of BAX
dimerization in Nut3 and 5FU-treated cells expressing shCTRL or shBID. BID depletion prevents BAX dimerization in response to 5FU
treatment. P-values shown in (D, E) were calculated by Student’s t-test (unpaired, two-tailed). Figure source data can be found in
Supplementary data.
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observed for HCT116 cells, caspase 8 knockdown impairs
BID cleavage, caspase 3 activation, PARP cleavage, and
apoptosis in this cell line (Supplementary Figure S4). In
sum, these data indicate that stimulus-speciﬁc activation of
the extrinsic apoptotic pathway involving p53, caspase 8, and
tBID is required for BAX activation and commitment to
apoptosis in our paradigm.
Differential activation of the extrinsic pathway requires
FADD, not TRADD
In an effort to understand in greater detail how Nut3 and 5FU
differ in their ability to trigger p53-dependent apoptosis, we
investigated the signalling pathway responsible for caspase 8
activation upon 5FU treatment. Of note, caspase 8 can be
directly activated downstream of death receptors, but also by
a death receptor-independent mechanism involving caspase 3
(von Haefen et al, 2003). To discriminate between these
possibilities, we established stable knockdown cell lines for
FADD and TRADD (shFADD and shTRADD), two important
death domain-containing adaptor proteins that transmit
death ligand signals from death receptors to caspase 8 (Jin
and El-Deiry, 2005). If 5FU-induced caspase 8 activation
requires either of these adaptor proteins, this would suggest
that caspase 8 is activated via death receptors in our experi-
mental setting. Indeed, we found that FADD depletion abro-
gates both caspase 3 activation and Annexin-V positivity,
whereas depletion of TRADD does not signiﬁcantly affect
either event (Figure 4A and B). Furthermore, shFADD cells
are impaired in their ability to activate BAX (Figure 4C).
Together, these results indicate that 5FU treatment causes
apoptosis through a FADD-dependent, TRADD-independent
pathway. Additionally, we observed that BID knockdown
impairs caspase 3 activation more than it does caspase 8
activation, providing additional evidence that caspase 8
activation occurs upstream of caspase 3 activation in 5FU-
treated HCT116 cells (Supplementary Figure S5). Thus, we
conclude that the key molecular event deﬁning cell fate
choice in our model system likely resides within the death
receptor pathway.
DR4 is required for BAX activation and apoptosis
We hypothesized that one or more death receptors acting
upstream of FADD may be differentially expressed upon p53
Figure 3 Caspase 8 activation is stimulus-speciﬁc, p53-dependent and required for BID cleavage and BAX activation. (A) Caspase 8 activation
is stimulus-speciﬁc (FL) indicates full-length caspase 8 (55–57kDa), Casp8* indicates the 43–41kDa cleavage products. (B) 5FU-induced
caspase 8 activation and BID cleavage in HCT116 cells are p53-dependent events. (C) Caspase 8 knockdown prevents caspase 3 activation and
PARP cleavage upon 5FU treatment. White line indicates cropping of intervening lanes from the same blot. (D) Apoptotic index assays show
that caspase 8 is required for 5FU-induced apoptosis. Data shown are the mean±s.d. P-values were calculated by Student’s t-test (unpaired,
two-tailed). (E) BID cleavage in 5FU-treated cells requires caspase 8. (F) Immunoblot analysis of 6A7 immunoprecipitates indicates that BAX
activation following 5FU treatment is both caspase 8- and BID-dependent. Figure source data can be found in Supplementary data.
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expression and cell surface localization of DR4 (TNFRSF10A/
APO2/TRAIL-R1), DR5 (TNFRSF10B/TRAIL-R2/KILLER) and
FAS (TNFRSF6/APO-1/CD95), all of which require FADD to
mediate pro-apoptotic signalling and have also been pre-
viously described as p53 target genes (Wu et al, 1997;
Muller et al, 1998; Liu et al, 2004; Jin and El-Deiry, 2005).
Western blot analysis of the three death receptors revealed
markedly different, stimulus-speciﬁc patterns of expression
for DR4, DR5, and FAS (Figure 5A). At an early time point
(8h), Nut3 induces DR4 to the same extent as 5FU; however,
in Nut3-treated cells, DR4 protein returns to basal levels at
later time points (16 and 24h) but remains elevated in 5FU-
treated cells. In contrast, DR5 expression is induced equally
by Nut3 and 5FU at 8h, but Nut3-treated cells maintain
steady DR5 expression, whereas DR5 protein levels decrease
slightly in 5FU-treated cells at later time points. Lastly, both
Nut3 and 5FU treatments lead to sustained FAS induction
over the course of the experiment, although 5FU does induce
FAS to a greater extent than Nut3. Next, we investigated the
cell surface expression of DR4, DR5, and FAS by ﬂow
cytometry, which is a more accurate measurement of the
active pool of these receptors. In close agreement with total
protein levels, 5FU treatment leads to higher cell surface
levels of DR4 than does Nut3 treatment, with mean ﬂuores-
cence indices (MFIs) of 1.34±0.04 and 1.04±0.03, respec-
tively (Figure 5B). In contrast, despite differences in the total
protein levels seen by western blot, cell surface levels of FAS
and DR5 are nearly identical in cells treated with Nut3 or 5FU
(MFI
FAS 2.10±0.04 and 2.07±0.05; MFI
DR5 1.47±0.08 and
1.40±0.12). Based on these results, we focused our efforts on
testing the possible role of DR4 in 5FU-induced apoptosis.
Interestingly, whereas FAS knockdown has no signiﬁcant
effect on cell death, knocking down DR4 expression signiﬁ-
cantly attenuates 5FU-induced apoptosis (Figure 5C). Next,
we tested if DR4 is required for 5FU-induced BAX activation.
Indeed, immunoprecipitation of activated BAX with the 6A7
antibody revealed that DR4 ablation blocks BAX activation
upon 5FU treatment (Figure 5D). Importantly, DR5 has been
previously shown to contribute to 5FU-induced apoptosis
(Wang and El-Deiry, 2004), and we conﬁrmed these results
in our system (Supplementary Figure S6). Thus, although
both DR4 and DR5 mediate the apoptotic effects of this
genotoxic agent, only DR4 is differentially activated in 5FU-
treated cells as compared with Nut3-treated cells, and thus is
more likely to deﬁne the cell fate choice.
Stimulus-speciﬁc DR4 expression is achieved via
stabilization of the DR4 mRNA
Next, we investigated the mechanism driving stimulus-
speciﬁc activation of DR4. Interestingly, Q-RT–PCR analysis
revealed stimulus-speciﬁc induction of the DR4 mRNA over
time (Figure 6A). Importantly, full induction of DR4 mRNA
requires p53; however, the mRNA still accumulates B2-fold
in p53-null cells, suggesting the combined action of p53-
dependent and p53-independent events. In contrast, the p21
mRNA is equally induced by both drugs in a p53-dependent
manner. Since the DR4 locus is a known direct transcriptional
target of p53 (Liu et al, 2004), we hypothesized that stimulus-
speciﬁc transcription of DR4 could explain differential DR4
expression. To test this, we measured initiating and elongat-
ing forms of RNA polymerase II (Ser5-phospho-RNAPII and
Ser2-phospho-RNAPII, respectively) at the DR4 locus by
chromatin immunoprecipitation (ChIP) assays. Activation of
p53 with Nut3 or 5FU for 12h results in increased S5P-
RNAPII occupancy at the DR4 promoter region as well as
within the gene body, indicating increased transcription in-
itiation with both stimuli (Figure 6B). Likewise, S2P-RNAPII
also increases throughout the DR4 gene body after both
treatments, surprisingly demonstrating equivalent increases
in transcriptional elongation. We employed the p21 locus for
comparison purposes, which displays strong RNAPII activa-
tion by both p53-activating agents. Taken together, these
results suggest that the stimulus-speciﬁc accumulation of
DR4 mRNA seen in our system cannot be adequately ex-
plained by stimulus-speciﬁc differences in DR4 transcription.
Therefore, we asked whether Nut3 and 5FU differentially
affect DR4 mRNA stability. Indeed, mRNA half-life assays
demonstrate that 5FU treatment has a signiﬁcant effect on
DR4 mRNA stability, nearly doubling its half-life relative to
DMSO- or Nut3-treated cells (Figure 6C; Supplementary
Figure S7). Interestingly, the DR4 mRNA was also stabilized
in p53
 /  cells. Taken together, these data suggest that Nut3
and 5FU treatments lead to an equal but modest induction of
DR4 transcription, but that stimulus-speciﬁc accumulation of
DR4 following 5FU treatment results from increased stabili-
zation of the DR4 mRNA. Of note, the NOXA mRNA, which is
also induced in a p53-independent manner upon 5FU treat-
ment (Supplementary Figure S2), is also strongly stabilized
by 5FU regardless of p53 status. However, mRNA stabiliza-
tion upon 5FU is not a universal phenomenon, as it is not
observed for the p53 target gene MDM2 (Figure 6C). Thus, we
conclude that 5FU induces mRNA stabilization of a subset of
Figure 4 Stimulus-speciﬁc activation of the extrinsic apoptotic pathway is mediated by FADD. (A) Caspase 3 activation requires the adaptor protein
FADD, not TRADD. (B) Apoptotic index assays demonstrate that FADD, not TRADD, is required for full induction of apoptosis upon 5FU treatment.
Data shown are the mean±s.d. P-values were calculated by Student’s t-test (unpaired, two-tailed). (C) Immunoblot analysis of 6A7 immuno-
precipitates indicates that BAX activation following 5FU treatment is FADD-dependent. Figure source data can be found in Supplementary data.
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this event contributes to cell fate choice upon p53 activation.
Conserved action of the DR4/FADD/caspase 8/tBID axis
In order to test whether the mechanism of cell fate choice
identiﬁed in HCT116 colorectal cancer cells is conserved in
cancer cells of different tissue origin, we employed H460 cells
(non-small cell lung cancer), which also undergo cell-cycle
arrest upon Nut3 treatment (Tovar et al, 2006). Indeed, we
found that although both Nut3 and 5FU activate p53 in this
cell line, only 5FU triggers caspase 8 activation, BID cleavage
and caspase 3 activation (Figure 7A). As observed in HCT116
cells, differential induction of apoptosis correlates with high-
er expression of DR4 protein and mRNA at late time points of
5FU treatment (Figure 7A and B). Importantly, knockdown of
BID, caspase 8, DR4, or FADD decreases BID cleavage,
activation of caspase 3 and Annexin-V staining in this cell
line (Figure 7C and D). Thus, we conclude that the DR4/
FADD/caspase 8/tBID axis contributes to cell fate choice
across cancer cells of different origins.
Finally, we investigated whether this same pathway is
activated by other genotoxic stimuli. To test this, we per-
formed a side-by-side comparison of the effects of Nut3, 5FU,
doxorubicin, camptothecin, etoposide, and Ultra Violet Light
C (UVC) on caspase activation and apoptosis. Although all of
these drugs lead to p53 activation, we and others have
previously shown that only 5FU and UVC lead to rapid
apoptosis in HCT116 cells, whereas the topoisomerase inhi-
bitors lead to cell-cycle arrest mostly in G2/M, and to a lesser
extent, in G1 (Donner et al, 2007a; Bunz et al, 1998, 1999;
Gomes and Espinosa, 2010). Interestingly, only 5FU and UVC
lead to activation of caspase 8 (Supplementary Figure S9).
In order to deﬁne if 5FU and UVC induce apoptosis by
identical mechanisms, we tested the impact of shRNAs
against BID, caspase 8, DR4, and FADD, as well as p53
knockout, on UVC-induced apoptosis. Expectedly, p53 knock-
out signiﬁcantly reduces caspase 3 activation upon UVC
treatment. Importantly, we found that whereas knockdown
of BID, caspase 8, or FADD impairs activation of caspase 3
following UVC treatment, the effects of DR4 knockdown are
negligible. Thus, we conclude that both 5FU and UVC require
a functional FADD/caspase 8/BID axis to induce apoptosis,
but that only 5FU requires DR4, suggesting that UVC utilizes
an alternative pathway for caspase 8 activation.
Discussion
Given the high prevalence of cancer and the fact that p53 is
the most commonly mutated tumour suppressor gene,
anomalies in the p53 network cause an unacceptable amount
of disease and death. Despite thousands of publications on
this important tumour suppressor, there is still much that we
do not know. In particular, a key question remains unan-
swered: what determines the cellular response to p53 activa-
tion? Given the intrinsically p53-centric nature of the ﬁeld,
most efforts in this area have focused on regulatory events
affecting the p53 molecule itself. These efforts have produced
several models where the cellular outcome upon p53 activa-
tion is deﬁned by p53 post-translational modiﬁcations and/or
p53-binding proteins (Samuels-Lev et al, 2001; Sykes et al,
2006; Tang et al, 2006; Das et al, 2007). In this report, we took
an alternative approach and investigated this problem from a
gene network perspective, where the p53 molecule is
embedded in a gene circuit composed of its many target
genes and their interactors (Figure 8). Our efforts identiﬁed
key regulatory events affecting cell fate choice that seem to
Figure 5 DR4 is required for stimulus-speciﬁc BAX activation and apoptosis. (A) Immunoblots show that total protein levels of the DR4 and
FAS death receptors, but not DR5, are higher in 5FU-treated cells than in those treated with Nut3. (*) Indicates a non-speciﬁc band. (B) Nut3
fails to induce DR4 cell surface expression as measured by ﬂow cytometry. Nut3 and 5FU induce DR5 and FAS cell surface localization equally.
Data shown are representative of a least three independent experiments. (C) Apoptotic index assays show that DR4, but not FAS, is required for
5FU-induced apoptosis (see Supplementary Figure S6 for western blot analysis of FAS knockdown). Data shown are the mean±s.d. P-values
were calculated by Student’s t-test (unpaired, two-tailed). (D) Immunoblot analysis of 6A7 immunoprecipitates indicates that BAX activation
following 5FU treatment is DR4-dependent. Figure source data can be found in Supplementary data.
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be explained by any of the previous models proposing that
cell fate choice is determined by differential transcriptional
regulation of cell-cycle arrest genes, such as p21 and 14-3-3s,
versus the apoptotic genes PUMA and BAX (Figure 1). Thus,
we turned our attention towards other gene modules within
the network that could behave as molecular switches govern-
ing cell fate choice. This led to the unexpected discovery that
the key differential event between arresting and apoptotic
cells was activation of the extrinsic apoptotic pathway down-
stream of DR4 and DR5. As discussed below, these observa-
tions contribute to our understanding of several molecular
processes including, but not restricted to, regulation of p53
DNA-binding and transactivation activities, regulation of the
intrinsic and extrinsic apoptotic pathways by p53, and
modulation of BAX activity by BH3-only proteins.
First and foremost, p53 is a transcription factor. Naturally,
many efforts aimed at understanding context-dependent p53
responses have focused on the regulation of its DNA-binding
and transactivation activities. Several studies have indicated
that these biochemical steps can be regulated by stress-
induced p53 post-translational modiﬁcations and p53-binding
proteins. Repeatedly, the p53 target genes reported to
be affected by these modiﬁcations and cofactors are p21,
14-3-3s, PUMA, and BAX. For example, the HZF protein was
shown to associate with p53 to allow binding and transacti-
vation of the p21 and 14-3-3s promoters while blocking
binding to the BAX locus (Das et al, 2007). Conversely, the
p53-binding protein ASPP2 was shown to increase binding to
and transactivation of BAX, but not p21 (Samuels-Lev et al,
2001). Similarly, acetylation of lysine 120 in the p53 DNA-
binding domain was shown to stimulate transactivation of
PUMA, but not p21 (Sykes et al, 2006; Tang et al, 2006).
However, none of these gene-speciﬁc effects seem to play a
role in our paradigm, as p21, 14-3-3s, PUMA, and BAX are
equally induced by p53 in Nut3- and 5FU-treated cells. Of
note, prior studies have shown equal p21 upregulation in
cells that undergo cell-cycle arrest versus those that undergo
apoptosis upon p53 activation (el-Deiry et al, 1994).
In contrast to the prevalent models, our research revealed
an unprecedented role for the death receptor DR4 in p53-
dependent cell fate choice. DR4 is activated in a stimulus-
speciﬁc manner and is required to overcome BAX poising at
the mitochondria, which also requires both caspase 8 and
Figure 6 Stimulus-speciﬁc stabilization of the DR4 mRNA. (A) Q-RT–PCR analysis reveals that the DR4 mRNA, but not the p21 mRNA,
accumulates more strongly in 5FU-treated cells. (B) ChIP analysis of the DR4 and p21 loci show increased levels of initiating (S5P-RNAPII) and
elongating (S2P-RNAPII) forms of RNAPII in response to p53 activation by both Nut3 and 5FU. Grey regions represent the transcribed region of
each locus, arrows indicate transcription start sites, black boxes represent exons, and black dashes indicate the position of PCR amplicons used
for analysis of ChIP-enriched DNA. (C) Schematic of experimental procedure for DR4 mRNA half-life determination (top). Following 12h of
DMSO, Nut3 or 5FU treatment of HCT116 cells of different p53 status, RNA synthesis was halted by ActD and the levels of DR4, NOXA and
MDM2 mRNA levels were measured over the time, revealing that 5FU treatment leads to stabilization of the DR4 and NOXA mRNAs in a
p53-independent fashion. The numbers to the right indicate the mRNA half-lives for the corresponding mRNAs in HCT116 p53
þ/þ cells treated
with DMSO (black) or 5FU (blue). A table with all half-life measurements can be found in Supplementary Figure S7.
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induce apoptosis in a majority of cancer cell lines is that
additional, p53-independent events may be required to over-
come oncogenic pro-survival signalling. Since 5FU has pleio-
tropic effects on cellular metabolism whereas Nut3 activates
p53 very speciﬁcally, it is likely that 5FU treatment provides
both p53-dependent and -independent signals to efﬁciently
induce apoptosis. Consistent with this idea, increased expres-
sion of DR4 mRNA after 5FU treatment is not completely
abrogated in HCT116 p53
 /  cells (Figure 6A), suggesting
that full DR4 induction requires both p53 and additional,
unidentiﬁed factors. In fact, our research revealed that sti-
mulus-speciﬁc induction of DR4 mRNA is not due to a
differential ability of Nut3 and 5FU to transactivate the DR4
locus, but rather to p53-independent mRNA stabilization
upon 5FU treatment. Thus, the coordinated action of p53
and other complementary stress-activated pathways tips the
balance towards the apoptotic response in 5FU-treated cells.
Unfortunately, almost nothing is known about the regulatory
factors governing DR4 mRNA turnover, although one study
has shown that DR4 mRNA levels are increased in cells that
lack the RNA-binding protein HuR (Ghosh et al, 2009).
Interestingly, we found that the NOXA mRNA was also
stabilized in a p53-independent manner upon 5FU treatment,
yet the MDM2 mRNA was not affected in this way. These
observations point to the action of one or more gene-speciﬁc
regulators of mRNA stability whose activities are likely
regulated by genotoxic stress. Future studies will be required
to identify and characterize these regulators.
It is important to note that although we focused our efforts
on the role of DR4 in cell fate choice, it has been amply
demonstrated that DR5 also contributes to the p53 apoptotic
response in cells treated with 5FU and other genotoxic agents.
Elegant work by the El-Deiry group showed that knockdown
Figure 7 The DR4/FADD/caspase 8/tBID axis also deﬁnes cell fate choice in the H460 lung cancer cell line. (A) Western blot analysis of H460 cells
shows that both Nut3 and 5FU activate p53 effectively, yet only 5FU leads to caspase 8 activation, tBID formation and caspase 3 activation.
Differential cell fate choice correlates with higher levels of DR4 at late time points after 5FU treatment. (B) Q-RT–PCR analysis shows that the DR4
mRNA accumulates only in 5FU-treated H460 cells. (C) Knockdown of BID, caspase 8, DR4, or FADD impairs both tBID formation and activation of
the executioner caspase 3. Immunoblot assessment of knockdown efﬁciency in H460 cells can be found in Supplementary Figure S8. (D)A p o p t o t i c
index assays reveal that BID, caspase 8, DR4, and FADD are all required for efﬁcient induction of apoptosis upon 5FU treatment. Data shown are the
mean±s.d. The indicated P-values represent the statistical signiﬁcance of the 5FU-treated value for the respective knockdown line relative to the
CTRL shRNA value and were calculated by Student’s t-test (unpaired, two-tailed). Figure source data can be found in Supplementary data.
Figure 8 Model of stimulus-speciﬁc conﬁgurations of the p53
network deﬁning cell fate choice in response to Nutlin-3 and 5FU.
See Discussion for details.
Mechanisms of cell fate choice to p53 activation
RE Henry et al
The EMBO Journal VOL 31 | NO 5 | 2012 &2012 European Molecular Biology Organization 1274of DR5 reduces 5FU-induced cell death of HCT116 cells and
reduces tumour growth in vivo (Wang and El-Deiry, 2004). In
mice, where there is a single pro-apoptotic TRAIL receptor
that is transactivated by p53 (likely a hybrid of DR4 and
DR5), gene knockout experiments showed that this pathway
contributes to p53-dependent, ionizing radiation-induced
apoptosis in various tissues (Finnberg et al, 2005). Since
DR4 and DR5 bind the same ligand, it is not clear if and
how they have specialized to mediate activation of the
extrinsic apoptotic pathway in different contexts. In this
regard, our work shows that while both receptors are induced
upon 5FU treatment and required for 5FU-induced apoptosis,
DR4 is not activated upon non-genotoxic activation of p53
with Nut3, thus revealing important regulatory differences
between these two genes in human cells. Interestingly, in
response to ionizing radiation, p53 activation in mice leads to
DR4/DR5 induction in tissues that undergo apoptosis but not
in those that undergo cell-cycle arrest (Burns et al,2 0 0 1 ;
Fei et al, 2002; Finnberg et al, 2005). Thus, differential
activation of the extrinsic pathway downstream of DR4
and/or DR5 could be a better predictor of the tissue-speciﬁc
responses elicited by p53 activation in human patients, as
compared with activation of p21 or some mitochondrial
apoptotic factors, which seem to be activated regardless of
outcome in various scenarios.
Regulation of BAX activity is a critical event in apoptosis.
BAX mediates permeabilization of the outer mitochondrial
membrane for release of pro-apoptotic molecules such as
cytochrome C and SMAC/DIABLO (Jin and El-Deiry, 2005).
Members of the BCL2 family of pro-survival factors bind to
BAX and prevent its activation (Jin and El-Deiry, 2005).
Members of the BH3-only family of apoptotic proteins pro-
mote BAX activity by: (1) binding to BCL2 family members
and preventing their interaction with BAX (‘derepression/
sensitiser’ mechanism) and/or (2) binding to and allosteri-
cally activating BAX (‘direct activation’ mechanism) (Jin and
El-Deiry, 2005). The precise contribution of different BH3-
only proteins to the ‘derepression’ versus ‘direct activation’
mechanisms is currently the subject of intense debate and is
under investigation by several groups. This debate is clearly
illustrated by PUMA, which has been proposed to mediate
apoptosis by engaging multiple BCL2 family members with-
out binding BAX or BAK (Willis et al, 2007), but also shown
to directly activate BAX by triggering both its mitochondrial
translocation and oligomerization (Kim et al, 2009). These
models are not necessarily mutually exclusive and it is
possible that PUMA contributes differentially to each me-
chanism in a context-dependent fashion. In this regard, our
results illuminate a novel facet of PUMA in p53-dependent
apoptosis. While there is no doubt that PUMA contributes to
p53-dependent apoptosis in response to 5FU and other geno-
toxic agents in HCT116 and other cell types (Nakano and
Vousden, 2001; Yu et al, 2001; Chipuk et al, 2005; Gomes and
Espinosa, 2010), our analyses clearly indicate that transacti-
vation of endogenous PUMA by p53 is not sufﬁcient to induce
apoptosis. In our system, total and mitochondrial levels of
PUMA protein are identical between arresting and apoptotic
cells, revealing the requirement for additional signals to
induce cell death. Of note, we and others have shown that
ectopic PUMA overexpression is sufﬁcient to induce apopto-
sis in HCT116 cells and many other cell types (Nakano and
Vousden, 2001; Yu et al, 2001; Gomes and Espinosa, 2010),
which indicates that these cells can be driven into apoptosis
by the mass action of BH3-only proteins. Thus, overexpres-
sion experiments must be interpreted carefully. One possibi-
lity is that cells are protected from the killing effects of
endogenous PUMA by the action of survival factors, some
of which may be induced by Nut3 itself. Indeed, our previous
work showed that HCT116 cells are protected from the killing
effects of Nut3 by the fact that p53 induces p21, 14-3-3s, and
miR-34a, three factors mediating cell-cycle arrest downstream
of p53 and thus partially protecting from apoptosis (Paris
et al, 2008). In fact, we found that HCT116 p21
 /  14-3-3s
 / 
cells where miR-34a is inactivated with ‘antagomirs’ fail to
properly arrest and show signs of apoptosis upon prolonged
Nut3 treatment. Additionally, we reported that cell lines
where Nut3 induces rapid apoptosis show impaired induction
of one or more of these cell-cycle inhibitors. In the extreme
case of the BV173 chronic myelogenous leukaemia cell line,
which undergoes rapid apoptosis within 24h of Nut3 treat-
ment, we found that the p21 mRNA is rapidly degraded and
the p21 protein never expressed, that the 14-3-3s promoter is
silenced by DNA methylation and that the primary transcript
for miR-34a is not processed into the mature microRNA. In
addition to the effect of these cell-cycle inhibitors, HCT116
cells are also protected from the killing effects of PUMA
by members of the BCL2 family. In fact, we and others
have found that knockdown of BCL2 sensitizes cells to
Nut3-induced apoptosis and that the BH3 mimetic ABT-737
synergizes with Nut3 to induce cell death (Sullivan and
Espinosa, unpublished results; Wade et al, 2008).
One key observation from our present work is that arrest-
ing cells are primed for apoptosis by having translocated BAX
to the mitochondria, but this form of BAX is not fully
activated and remains poised in a monomeric state.
Importantly, it has been shown that BAX is activated in a
stepwise fashion, where two distinct biochemical steps med-
iate membrane translocation and oligomerization (Kim et al,
2009). In the simplest interpretation, PUMA induction suf-
ﬁces only to induce the ﬁrst biochemical step in our system.
Our results indicate that tBID then completes BAX activation
at the mitochondria by inducing its oligomerization.
Although both PUMA and tBID have been considered equally
competent to induce both steps of BAX activation in certain
cell-free assays (Kim et al, 2009), our results are more
consistent with a model where PUMA and tBID cooperate
to induce BAX activation. Functional collaboration between
PUMA and tBID has been observed in other cell-free assays,
where pre-treatment of mitochondria with PUMA BH3
domain peptides sensitized them to tBID-induced permeabi-
lization by B100–200-fold (Chipuk and Green, 2009).
Furthermore, overexpression of PUMA is signiﬁcantly less
efﬁcient at inducing apoptosis in bid
 /  MEFs as compared
with wild-type cells (Chipuk and Green, 2009). Our results
reinforce the importance of this cooperation in cell fate choice
and identify a key biochemical event that could be modulated
to drive cells into alternative p53 responses. It remains to be
determined to what degree this cooperation between the
intrinsic and extrinsic pathways is conserved across diverse
cell types. Our ﬁnding that the DR4/FADD/caspase 8/tBID
pathway deﬁnes cell fate choice in both colorectal cancer and
lung cancer cells suggests that it is not a rare event.
Interestingly, the El-Deiry group has recently shown that
the intrinsic pathway may rely on extrinsic signals in more
Mechanisms of cell fate choice to p53 activation
RE Henry et al
&2012 European Molecular Biology Organization The EMBO Journal VOL 31 | NO 5 | 2012 1275scenarios than previously expected (Kuribayashi et al, 2011).
In fact, they found that dr4/5
 /  and puma
 /  animals do
not show additive protection from radiation-induced apopto-
sis in any of the investigated tissues.
In the post-genome era, the advent of functional genomics
and proteomics has accelerated the cataloguing of genetic
interactions and created a view of gene networks where
degeneracy, redundancy, and context dependency are the
norm. It is in this scenario that efforts to dissect how a ﬁnite
number of gene modules adopt stimulus- and cell type-
speciﬁc conﬁgurations to generate a plethora of biological
responses become critical. Given the biomedical relevance of
the p53 network and the validity of p53 as a bona-ﬁde
therapeutic target in cancer, advances such as those reported
here will bring us closer to the development of effective p53-
based therapies for the selective elimination of cancer cells.
Materials and methods
Cell culture
Cells were grown in McCoy’s 5A (HCT116), DMEM (RKO), or
RPMI1640 (H460) medium supplemented with 10% FBS (Sigma-
Aldrich) and antibiotic/antimycotic mix (Invitrogen) at 371C/5.0%
CO2. Unless otherwise noted, DMSO vehicle control (Sigma-
Aldrich), Nutlin-3R (Nut3; Cayman Chemical), and 5FU (Sigma-
Aldrich) were used at 0.1%, 10.0, and 375.0mM, respectively.
Doxorubicin (Sigma-Aldrich), Camptothecin (Sigma-Aldrich), and
Etoposide (Sigma-Aldrich) were used at 0.5mM, 2.0mM, and 1.0mg/
ml, respectively. For UVC irradiation of HCT116 cells, media was
aspirated from the plate prior to treatment with UVC (50J/m
2)i na
UV Stratalinker
s 2400 (Stratagene). Media was then replaced and
the cells incubated at 371C/5.0% CO2 for 24h prior to harvesting for
western blot analysis.
Western blots and antibodies
Protein preparation, quantiﬁcation, and immunoblot analyses were
performed as previously described (Gomes et al, 2006). Antibody
information is supplied in Supplementary Table SI.
Q-RT–PCR
RNA extractions, cDNA synthesis, and Q-RT–PCR were performed
as previously described (Gomes et al, 2006). Brieﬂy, total RNA was
isolated using an RNeasy kit (Qiagen) and ﬁrst-strand cDNA was
synthesized using the qScript kit (Quanta Biosciences) according to
the manufacturer’s instructions. cDNA was analysed by Q-RT–PCR
Absolute Quantiﬁcation method (SYBR green, ABI) on an ABI
7900HT instrument. Primer sequences are listed in Supplementary
Table SII.
shRNA-mediated knockdown
shRNAs were designed using the PSICOLIGOMAKER 1.5 software,
freely available from the Jacks Lab website (http://web.mit.edu/
jacks-lab/protocols/pSico.html), and cloned into the pLL3.7
expression vector. Commercially available shRNAs pre-cloned into
the pLKO.1-Puro vector (shCTRL and shDR4) were purchased from
Sigma-Aldrich. Oligonucleotide sequences for all shRNAs used in
this study are listed in Supplementary Table SIII. Lentiviral particles
were produced in HEK293FT packaging cells. HCT116 and RKO cells
were transduced with 0.45mm-ﬁltered viral supernatants. Selection
of stably transduced cells was carried out for 2–7 days with either
100.0mg/ml G418 or 10.0mg/ml puromycin (Sigma-Aldrich).
ChIP and Q–PCR
ChIP assays were performed as described in Gomes et al (2006).
Brieﬂy, cells were treated for 12h with DMSO, Nut3, or 5FU,
ﬁxed with 1.0% formaldehyde and harvested for whole-cell lysate
preparation in RIPA buffer. In all, 1.0mg of protein lysate was
used per ChIP with the indicated antibodies (Supplementary
Table SI) and Protein-G sepharose beads (GE Healthcare).
ChIP-enriched DNA was analysed by Q-PCR as described in Gomes
et al (2006). See Supplementary Table SIV for Q–PCR primer
sequences.
DR4 mRNA half-life determination
Cells were treated with DMSO, Nut3, or 5FU for 12h, followed by
the addition of 10.0mg/ml Actinomycin D (ActD; Sigma-Aldrich) to
the culture medium. Total RNA was isolated at several time points
after the addition of ActD, reverse-transcribed and subjected to Q-
RT–PCR analysis as described above.
Flow cytometry
Apoptotic index assays were performed as described in Gomes et al
(2006). Data were collected on a Cyan-ADP ﬂow cytometer (Dako)
and analysed using Summit 5.3 software (Beckman-Coulter).
Quantiﬁcation of cell surface death receptor levels
HCT116 cells were treated for 24h, trypsinized, and resuspended in
1.0% BSA (Fraction V) in PBS. In all, 1 10
5 cells were labelled with
the appropriate antibody or isotype control for 1.0h at 251C,
washed with 1% BSA/PBS, and stained with secondary antibody for
1.0h at 251C in the dark. Flow cytometry was carried out as
described above. MFIs were calculated as the ratio between the
mean ﬂuorescence value of the speciﬁc antibody and that of the
appropriate isotype control. Histograms were created using the
FlowJo Software package (Tree Star, Inc.). Antibodies used for
detection are listed in Supplementary Table SI.
Mitochondrial puriﬁcation and crosslinking
Subcellular fractionation was performed as described in Pallotti and
Lenaz (2007). Brieﬂy, cells were washed with cold PBS, resus-
pended in swelling buffer (10.0mM Tris–HCl pH 7.5, 10.0mM NaCl,
1.5mM MgCl2), and incubated on ice for 5min. Cell suspensions
were adjusted to 250.0mM sucrose and dounce homogenized.
Undisrupted cells and large cellular fragments were pelleted by
centrifugation at 1000g. Mitochondria in the supernatant were
separated from the cytosolic fraction by centrifugation at 10000g
and loaded onto a 1.0–1.7M discontinuous sucrose gradient.
Mitochondria were then recovered from the interphase. Isolated
mitochondria were either directly lysed in SDS buffer (1.0% SDS,
10.0% glycerol, 100.0mM Tris, pH 7.4) or ﬁrst crosslinked with
bismaleimidohexane (Pierce) using the manufacturer’s protocol
prior to lysis. Samples were then analysed by western blot.
BAX immunoprecipitation
Immunoprecipitation of activated BAX protein was performed as
described (Kim et al, 2009) with minor modiﬁcations. Cells were
treated with DMSO, Nut3, or 5FU for 24h, washed once in PBS,
resuspended in 1.0% CHAPS Buffer (1.0% (w/v) CHAPS, 142.5mM
KCl, 2.0mM CaCl2, 20.0mM Tris–Cl, pH 7.4) and dounce
homogenized. Lysates were cleared by centrifugation (21000g for
20min at 41C). In all, 1.0mg of protein extract was pre-cleared with
Protein-G sepharose beads (GE Healthcare) for 1.5h at 41C and
incubated with 5.0mg of mouse 6A7 antibody (Trevigen) overnight
at 41C. IPs were washed with 1.0% CHAPS buffer, eluted by boiling
in 1  SDS–PAGE loading dye, and subjected to immunoblot
analysis.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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